Literature DB >> 6311908

Enzyme-linked immunosorbent assay for the detection of Epstein-Barr virus-induced antigens and antibodies.

L Sternås, J Luka, B Kallin, A Rosén, W Henle, G Henle, G Klein.   

Abstract

Two Epstein-Barr virus (EBV)-specific ELISA tests were developed. One, based on the use of crude extracts from virus producer cells highly induced in the presence of Ara C (providing EA + VCA- cells) or in the absence of the drug (providing EA + VCA + cells) is suitable for the detection of antibodies directed against antigen complexes associated with the lytic virus cycle; i.e., EA, VCA and presumably also MA. The second, performed with purified EBNA, can be used for the detection of antibodies to the transformation-associated nuclear antigen. The tests are expected to find application in the dissection of antibody responses of patients to various antigenic subcomponents, the monitoring of EBV-coded antigens during biochemical purification, and the screening of spent media from hybridoma cultures for EBV-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311908     DOI: 10.1016/0022-1759(83)90422-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Expression of an early Epstein-Barr virus antigen (EA-D) in E. coli. Brief report.

Authors:  D Roeckel; H Boos; N Mueller-Lantzsch
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

2.  Carboxyl-terminal domain of the Epstein-Barr virus nuclear antigen is highly immunogenic in man.

Authors:  G Milman; A L Scott; M S Cho; S C Hartman; D K Ades; G S Hayward; P F Ki; J T August; S D Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

3.  Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen.

Authors:  J Dillner; L Sternås; B Kallin; H Alexander; B Ehlin-Henriksson; H Jörnvall; G Klein; R Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.